ABVX (Abivax) Other Current Liabilities: $33.90 Mil (As of Mar. 2026)


ABVX Abivax SA ABVX
10 GF Score
Price $139.90
! 2 Warning Signs
View Full Analysis

What is Abivax Other Current Liabilities?

Abivax ABVX -0.62% 10 Other Current Liabilities is $33.90 Mil as of Mar. 2026. GuruFocus rates ABVX with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Abivax's other current liabilities for the quarter that ended in Mar. 2026 was $33.90 Mil.

Abivax's quarterly other current liabilities increased from Sep. 2025 ($18.86 Mil) to Dec. 2025 ($19.94 Mil) and increased from Dec. 2025 ($19.94 Mil) to Mar. 2026 ($33.90 Mil).

Abivax's annual other current liabilities declined from Dec. 2023 ($3.83 Mil) to Dec. 2024 ($0.56 Mil) but then increased from Dec. 2024 ($0.56 Mil) to Dec. 2025 ($19.94 Mil).

Abivax Other Current Liabilities Related Terms

Abivax Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Abivax's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Other Current Liabilities Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 3.73 3.83 0.56 19.94

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 4.23 18.86 19.94 33.90
ABVX
10GF Score
Abivax SA ABVX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $33.90 Mil mean?
Abivax (ABVX) has a Other Current Liabilities of $33.90 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Abivax.
Is Abivax's Other Current Liabilities too high?
Abivax's current Other Current Liabilities is $33.90 Mil. Overall, Abivax has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Other Current Liabilities compare to VRTX and REGN?
Abivax's Other Current Liabilities of $33.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Abivax. Abivax's current Other Current Liabilities is $33.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (ABVX) has a current Other Current Liabilities of $33.90 Mil. The current Other Current Liabilities is $33.90 Mil. Abivax's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Abivax (ABVX), the current Other Current Liabilities is $33.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
10GF Score

Get the complete analysis for ABVX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$139.90
Price